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Introduction
Rationale
This report is aimed at Directors of Public Health and Pharmaceutical Advisers in
primary care organisations, and other stakeholders interested in community
pharmacy’s contribution to public health. It is one of a series of reports examining the
evidence relating to community pharmacy’s contribution to improving the public’s
health jointly commissioned by the charity PharmacyHealthLink (formerly the
Pharmacy Healthcare Scheme)1 and the RPSGB.2 The first of these reports3 reviewed
1 PharmacyHealthLink is an independent charity that aims to promote and improve the public’s health
through pharmacy.
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the UK and international research literature from 1990-2001, while the second4
considered the UK non-peer reviewed literature from 1990-2002. A third report
synthesises the findings from the two reports, and a subsequent update of report one
makes recommendations for action.5
During initial discussions it was acknowledged that a review of both the published and
unpublished literature could only provide a retrospective view of relevant work carried
out in the field. Consequently it was decided to undertake a survey of existing health
promotion6 and public health7 initiatives in community pharmacies concurrently with
the review of the published and unpublished literature.
The objectives of the survey and subsequent report were to:
 Produce an outline of current and recent local health promotion and public health
initiatives involving community pharmacies in the UK.
 Identify and describe similar initiatives in Europe, Australia and North America.
 Use in-depth ‘case studies’ to provide a descriptive analysis of innovative or
successful projects and to investigate the perspectives of key stakeholders
regarding the current and future role of community pharmacists in health
improvement.
Method
A questionnaire (See Appendix 1) was used to gather data on local health
improvement projects involving community pharmacists in England, Wales, Scotland
and Northern Ireland that had taken place in 1998 or later. Previous surveys 8 of
activity have been conducted in the UK, but there had been no such data collection
since 1998.
The survey aimed to capture data on as many projects as possible and to obtain
systematic details about their context, operation and evaluation. The geographical
scope of the work made face-to-face interviews impossible and a telephone survey
was rejected as time-consuming and impractical. Instead the survey was circulated by
e-mail. The survey pro forma, as agreed with the research commissioners, asked for
2 The Royal Pharmaceutical Society of Great Britain is the regulatory and professional development
body for pharmacy in England, Scotland and Wales. It has responsibility for the registration of
pharmacists and pharmacy premises as well as for overseeing the development of pharmacy practice.
3 Blenkinsopp, A. Anderson, C. & Armstrong, M. (2003).
4 Anderson, C., Blenkinsopp, A. & Armstrong, M. (2003).
5 www.pharmacyhealthlink.org.uk for PDF copies of all reports.
6 The Ottawa Charter for Health Promotion (WHO, 1986) states that ‘Health promotion is the process
of enabling people to increase control over, and to improve, their health’.
7 Public health has been defined as ‘the science and art of preventing disease, prolonging life and
promoting health through organised efforts of society.’ (Acheson Inquiry into the Future Development
of the Public Health Function, 1988).
8 Anderson, C Community pharmacy Health promotion activity in England: a survey of policy and
practice. Health Education Journal 1996; 55: 194-202
Anderson C Guidance for the development of health promotion by community pharmacists PharmJ
1998; 261: 771-775
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the following information: health topic, setting, intervention, training provided,
outcome measures, key findings and local partners.
Key sources of information were identified as:
 Health Promotion Units
 Health Authorities9 and primary care organisations
 Pharmaceutical Services Negotiating Committee (PSNC) community pharmacy
database (launched 14/04/02)
Key local informants were identified as:
 Heads of Health Promotion Units
 Centre for Pharmacy Postgraduate Education10 tutors
 Local Pharmaceutical Committee Secretaries
 Pharmaceutical Advisers
As the NHS was undergoing significant infrastructure changes at the time of the
survey11 and as there was no existing sampling frame, a number of strategies were
used to reach potential respondents. For Health Promotion Units the list of local units
and contacts on the Health Promotion England website was used.12 Each was
contacted by phone to identify the individual who would be most appropriate for the
survey. Centre for Pharmacy Postgraduate Education tutors received the survey by
email through their head office. PSNC distributed the survey to Local Pharmaceutical
Committee Secretaries and the PSNC community pharmacy database was accessed
when it became available in April 2002. Unfortunately, it was not possible to access
the database of all Pharmaceutical Advisers in England, but in Scotland, Wales and
Northern Ireland, key informants were identified and invited to complete the survey.
The National Pharmaceutical Association also shared information from their database
of community pharmacy health promotion projects.
Survey respondents were asked whether they were undertaking, or had undertaken,
any projects in the following areas: smoking cessation, sexual health, drug misuse,
heart disease prevention, health screening, diabetes, obesity and accident prevention.
They were also asked to provide information about any other areas in which pharmacy
health improvement work had been undertaken. For each specific project, the survey
requested the following information: geographical area, number of community
pharmacies participating and how they were selected, activities, funding, outcome
measures, any evaluation and collaborating agencies. The survey was distributed in
March 2001 with a reminder sent out in June 2001.
9 In April 2002 Health Authorities in England were superseded by Primary Care Trusts and Strategic
Health Authorities. The Survey was issued just before this re-organisation.
10 Centres for Pharmacy Postgraduate Education (CPPE) are the primary national providers of
postgraduate pharmacy education in the UK.
11 See Department of Health (2001). Shifting the Balance of Power: Securing Delivery. London:
Stationery Office. Available online: www.doh.gov.uk/shiftingthebalance for further details.
12 Since publication the list of contacts at HPUs has transferred to the Department of Health (England)
Communications Division.
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Whilst it was possible this data collection strategy may have led to some overlap or
duplication, it was intended to provide as complete a picture as possible of activity
across the UK. A matrix was constructed with an entry for each project reported,
arranged by health topic then geographical area. Details of service design,
participating pharmacies, key findings, outcome measures and any evaluation
undertaken were included. In February 2002 the matrix was distributed to
Pharmaceutical Advisers working in primary care to ask them to check the entries for
their area and report any additional projects.
International examples were drawn from a range of sources. One of the authors (CA)
had recently worked on a European project to draw together definitions, policy and
practice in health promotion in primary care.13 The report of this project was used to
identify relevant examples of community pharmacy initiatives across a range of topics
and selected informants in Europe, Australia and the United States were contacted to
obtain more information. A narrative report illustrating examples of international
innovative practice or development was produced.
Certain UK examples of innovative practice that were potentially transferable to other
areas were also selected for more detailed investigation. In-depth ‘case studies’ were
conducted for Manchester, Salford and Trafford Health Action Zone on the supply of
emergency hormonal contraception and in Greater Glasgow for drug use services. An
additional case study with Lloydspharmacy explored how a community pharmacy
could take a holistic view of health and make provision within its premises to create a
CHAT centre that would facilitate advice and support customers on the wider
determinants of health.
The case studies set out to investigate the perspectives of key stakeholders with
respect to the current and future involvement of community pharmacists in health
improvement activities. As a result, data collection consisted principally of two
strands:
 A profile of the relevant case study built through analysis of key documents and
reports;
 Face-to-face (or telephone) qualitative interviews conducted with local
stakeholders reflecting public health and pharmacy perspectives.
Summary of recommendations to run a ‘successful’ community pharmacy-based
health improvement initiative
1. Conduct a local ‘health needs assessment’ amongst regular users of the
pharmacy and local residents.
 Try to use existing ‘templates’ and ‘frameworks.’ To help you do this, for
example, contact the main pharmacy associations to see if they have any relevant
support material.
13 See Health promotion in primary health care: general practice and community pharmacy
www.univie.ac.at/phc/webindex.htm (accessed 18/08/03) for further details.
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 Contact and work with local pharmacy development groups, community pharmacy
facilitators and the local public health department where possible.
2. Recognise all the key influences on health, such as income and education, as
well as lifestyle issues such as smoking and diet.
 Work in active partnership with a wide range of health improvement organisations
particularly those that help reduce inequalities in health, both in the pharmacy and
in other settings such as primary care premises, schools and workplaces.
3. Initiate and design projects that reflect and utilise the pharmacy’s unique
position, and contribution to, the community.
 Define the ‘added value’ of community pharmacy – e.g. highlight increased access
to healthy people as well as ill, describe benefits of consultations being conducted
in an informal environment, etc.
 Determine how community pharmacy involvement can help deliver local targets
and other NHS performance measures (see below)
4. Try to find dedicated funding that will be sustainable in the longer term.
 Tap in to national agendas and select a topic area that is already a NHS or a local
priority.
 Make clear in funding proposals how the project will contribute to local and
national targets.
 Consider alternative sources of funding to ‘kick-start’ the project.
5. Build a committed network of participating community pharmacies.
 Enlist the support of local pharmacy bodies to the proposal such as Local
Pharmaceutical Committees, Pharmacy Development Group Facilitators or
Pharmaceutical Advisers.
 Discuss and agree terms of how the proposal might work
 Hold a local event to explain the project / proposal to interested community
pharmacists and their staff
 Identify, support and promote local ‘project champions’
6. Seek and maintain the support of other stakeholders.
 Hold a number of separate events or meetings to discuss and consult with non-
pharmacy stakeholders, such as local GPs and health service managers. Non-
pharmacy professionals, especially other public health practitioners and
specialists, can be strong supporters of community pharmacy-based health
improvement services and can be key to their long-term survival.
 Agree the way forward for the service and terms of how it would operate.
 Identify and support ‘non pharmacy’ project champions.
 Discuss funding arrangements and arrange fees to reward sustainable practices,
long-term commitment and high standards of service provision.
7. Provide training for all staff – preferably in a multidisciplinary environment.
 Ensure all staff taking part in the project has received training - ideally before the
service begins or as soon as possible after it starts.
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 Use nationally recognised standards and guidance where possible but adapt
training to local needs.
 Establish whether local protocols, e.g. use of patient group directions, need to be
followed and by which staff members. Provide specific training for this if
required.
 Ensure that key messages to be communicated to service users are consistent
across different health professionals and staff providing the service.
 Provide appropriate training on communication skills and use ‘role play’ scenarios
when dealing with sensitive health issues.
8. Focus on the needs of the service user.
 Ensure all staff are knowledgeable about the service and can provide helpful
advice in a professional and non-judgemental manner.
 Think about when the service might be accessed and by which target groups.
 Try to ensure the most knowledgeable or highly trained staff are available at busy
times.
 Provide a private consultation area in the pharmacies where conversations cannot
be overheard by others, and ensure that requirements for confidentiality and record
keeping are well publicised.
 Make sure that arrangements for services ‘out of hours’ and information that
‘signposts’ users to other relevant services are easily visible.
 Provide convenient ways for users to feedback their experiences of the service and
how it might be improved.
9. Carry out careful and thorough evaluation of the service.
 Build record-keeping and other ways of collecting meaningful information about
the project into the original service design.
 Make outcome measures clear from the start. These should reflect government or
local targets where possible.
 Allocate funds to the evaluation process (normally 15% of total project budget).
 Consider using independent evaluators. This may be done in collaboration with a
local university or other research and development centre.
10. Provide feedback to stakeholders and the public on progress of the service.
 Offer to hold a local event to publicise the results of your evaluation to
professional stakeholders, e.g. NHS managers, local GPs, other pharmacists.
 Consider providing information on updates and feedback on the service to users in
the pharmacy.
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The Survey
The email survey identified 184 projects. Returns were received from 78 primary care
organisations some identifying more than one project. Of these responses, 62 came
from former HA areas in England, 7 from Scotland, 4 from Northern Ireland and 5
from Wales. A further 34 projects were identified from PSNC community pharmacy
database.
The survey pro forma (See Appendix 1) asked for specific details about each project.
Some areas provided additional information but, in a few cases, very limited details
were returned. Details of individual projects recorded include setting, numbers of
pharmacies participating, outcome measures and any evaluation undertaken.14
The report summarises and synthesises findings by topic. Table 1 gives a breakdown
by health topics of the number of UK local projects identified. By far the most
commonly reported health topics were smoking cessation, drug misuse and sexual
health.
Table 1: Number of UK local projects by health topic
Topic No. of projects
reported
Smoking cessation 64
Drug misuse 44
Sexual health 31
Accident prevention 7
Health Screening – general 3
Heart disease 5
Diabetes 4
Obesity/weight reduction 3
Immunisation 2
Travel health 3
Other 18
TOTAL 184
14 More details on individual projects are available from the PharmacyHealthLink website:
www.pharmacyhealthlink.org.uk.
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Results: Projects Identified by the Email Survey
Smoking cessation – 64 projects
Smoking cessation services was the most commonly reported project. These were
usually at specialist level, and included the supply of nicotine replacement therapy.
Some schemes invited all pharmacies within the local area to participate. Others
focused on Health Action Zones, areas poorly covered by other smoking cessation
services or low-income clients. For example, in the Calderdale and Kirklees area they
aimed to recruit pharmacies in areas not covered by the local stop smoking advisers.
Many schemes identified outcome measures in line with the national data
requirements for stop smoking services; in particular the number of clients attending
and the number of self-reported ‘quitters’. Some areas added other indicators such as
the ‘client return rate for support’, which was assessed in a number of ways including
the number of requests for advice in a two-week or four-week period. Public uptake of
these services was generally good, with some schemes exceeding their targets. Stop
smoking co-ordinators, National Health Service specialist advisers and local health
promotion services were common partners in the development of community
pharmacy-based smoking cessation services.
Training for pharmacists ranged from an evening session to a two-day course. Only
four schemes did not include any form of training. In general, pharmacists were paid
to participate. Local arrangements varied considerably and in some cases included
longer-term elements. Examples include:
 Payment per client or per intervention.
 Fee for the first week’s supply of NRT and eight weeks’ counselling.
 Fee per client over a six-week period.
 Fee per monitoring form completed after four weeks.
 Initial payment, reimbursement for the NRT product supplied and a fee per
voucher.
Funding came from a variety of sources including Department of Health ‘ring fenced’
smoking cessation budgets, primary care organisations and Health Action Zones. At
the time of the initial survey (spring 2001), the availability of funding to continue
pharmacy-based smoking cessation services was uncertain. Nevertheless some areas
reported schemes continuing and some introduced new schemes later in 2001.
Innovative example of service provision
UK:
The ‘Trash the Ash’ campaign in Hull and East Riding incorporated a media
campaign supported by posters and information packs displayed in community
pharmacies. Smokers were encouraged to contact the local paper and pledge to stop
smoking for the New Year 2000. Over 450 did so. The project was supported by the
pharmacy development group, a local newspaper, the Hull and East Riding Health
Action Zone and the Humber Alliance on Tobacco.
Final Report 2005
10
Drug use – 44 projects
Thirty-six of the reported projects were for supervised methadone and/or sublingual
buprenorphine (Subutex) consumption, 6 were for needle/syringe exchange
programmes, one aimed to improve the dental health for users, and one prepared
pharmacists to train teachers about drug misuse.
Outcome measures for methadone supervision schemes included reductions in street
methadone use, accidental child overdoses, the presence of other drugs found at
urinalysis of clients, police reports of drug-related crime and acceptability to clients.
Needle and syringe exchange schemes used client numbers and items supplied and
returned as key outcomes. Evaluation was ongoing in most schemes.
Initial training was provided for almost all reported schemes and one area also trained
pharmacists new to the scheme. The CPPE’s Drug Misuse programme was widely
used. One scheme in the Forest of Dean area included a presentation from a
community pharmacist providing a methadone supervision service.
Collaboration with drug agencies and other local stakeholders was widespread. A
shared care scheme involving the methadone client, drug misuse key worker, GP and
community pharmacist was implemented in West Berkshire, and then extended to
East Berkshire through their community drugs teams.15
Innovative examples of service provision
UK:
The remuneration system for general practitioners and pharmacists in the Berkshire
project was based on treatment ‘slots’ of 12 months for which each professional
received £90. For pharmacists, the slot included up to 13 weeks of methadone
supervision within that period. By March 2001, almost 60% of local community
pharmacies had been involved in the scheme and over half had provided supervised
methadone consumption.16 The remuneration structure for the Greater Glasgow
Health Board service (see Case Study 1) included both retainer and item of service
elements and was designed to encourage pharmacists to provide the service seven
days a week so that the ‘take home’ methadone supply was reduced.
International:
A national study of community pharmacy-based methadone services in Australia
reported pharmacies having higher client retention rates than public methadone clinics
without pharmacists.17
For methadone various service specifications and remuneration systems operated,
many pharmacists were paid a £1 fee per supervised administration. In West Berkshire
pharmacists’ remuneration is based on treatment ‘slots’ of 12 months for which they
16 Pharmaceutical Journal, 2001. 266: 547-552.
17 Con Berbatis, personal communication.
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receive £90 per patient, the slot includes up to 13 weeks of methadone supervision
within that period In Gloucester pharmacists are limited to 20 ‘slots’ at any one time
and funded at £156 per ‘slot’ quarterly. Currently, there are approximately 4,000
individuals receiving daily supervised dispensing of methadone from 170 community
pharmacies in the Greater Glasgow Health Board area. Some pharmacies are
conducting 150 supervisions per day.
The remuneration structure includes both retainer and item of service elements and
was designed to encourage pharmacists to provide the service 7 days a week so that
the ‘take home’ methadone supply is reduced.
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Case Study One: Pharmacy services for drug users in Greater Glasgow –
supervised methadone dispensing and needle exchange schemes
Introduction and background
In Glasgow, as in many UK cities, drug use emerged as a serious public health and
criminal disorder problem during the 1980s and 1990s. The city has around 7,000 –
10,000 current or recent intravenous drug injectors out of a population of 916,000.18
Most typically use heroin but temazepam, diazepam, buprenorphine, dihydrocodeine
and oral morphine are also used.19 Multiple drug use is a significant concern.
Although less than 1% of drug injectors are known to be HIV positive, around 72%
are known to have the hepatitis C virus.20
Methadone was prescribed extensively to drug users in the 1970s and 1980s but was
later largely abandoned because of the absence of monitoring and surveillance support
in the community. However, by the early 1990s, general practitioners began to
prescribe methadone successfully in a controlled manner with the support of local
drug agencies.
Prior to the 1990s, community pharmacists were impeded from providing needle and
syringe exchange services for fear of prosecution under the common law crime of
‘reckless conduct’. However, growing awareness of the spread of HIV through
needle-sharing led to a softening of the law on reckless conduct and after 1988
pharmacists were allowed to sell up to five sets of injecting equipment per transaction.
Policy context
The impetus for greater pharmacy involvement in supervised consumption of
methadone emerged from a major review of drug use services by the Greater Glasgow
Health Board. Subsequently, the Glasgow Drug Problem Service was set-up with three
main priorities:
· Reducing or eliminating illicit injecting.
· An improvement in the general health of drug users.
· A reduction in the prevalence of drug use.
Pharmacy Involvement
18 Frischer et al. 1997; Ahmed 2000.
19 ISD, Scotland 2002.
20 Taylor et al. 2000.
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This review established a basis for pharmacy involvement in the supervised
consumption of methadone. In Glasgow, the Area Pharmaceutical Committee (the
Professional Advisory Committee) and the Area Pharmaceutical Contractors
Committee strongly supported the involvement of community pharmacies in
Supervised Consumption of Methadone (SCM). In particular, they recognised that
SCM should be provided through many pharmacies rather than from a single
identifiable centre. Since 1994, the supervision of methadone consumption by
pharmacists has effectively become standard practice for patients receiving
prescriptions for methadone.21
From April 2002, around 180 out of 215 pharmacies in the Greater Glasgow Health
Board area were dispensing methadone of which 170 (79%) were contracted by the
Health Board to supervise the consumption of methadone for 4,686 patients.22 Service
activity forms indicate that 87% of methadone doses dispensed by contracted
pharmacists are consumed on the premises. Furthermore, 91% of methadone
prescriptions issued by GPs in the Drug Misuse Clinic Scheme and 99% of
prescriptions issued by the Glasgow Drug Problem Service request supervised
consumption.23
Impact of the scheme
In addition to health improvements amongst drug users, the pharmacy SCM
programme is thought to have helped reduce drug-related crime in the Glasgow area
by minimising leakage of methadone onto the illicit drugs market.24 Some drug users
have been able to return to work or further education.
Service description – practical aspects of operating the scheme
The role of community pharmacists on the programme is to:
· ensure that adequate blood and tissue levels of methadone are maintained,
reducing the need for opiates;
· prevent the diversion of methadone onto the black market;
· make a daily assessment of patient compliance with the programme and the
general health and well-being of the patient;
· build a rapport with the patient that is beneficial from a health promotion and
public health viewpoint.
The Glasgow guidelines recommend that all pharmacies should have a written
protocol in place, for all staff to be aware of that protocol, and to specify the
procedures to be followed when a new patient enters the SCM programme and for
patients who attend regularly. The operational protocol requires details of the
following:
 patient medication records;
 identification of patients;
 prescription legality;
21 Roberts et al., 1998; Roberts, 2000.
22 Kay Roberts, personal communication.
23 Kay Roberts, personal communication.
24 Weinrich & Stuart, 2000.
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 preparation of daily doses;
 discrete and efficient supervision by the pharmacist;
 disposal of waste;
 doses to be collected when the pharmacy is closed;
 use of safety stickers for taking products home;
 confidentiality;
 behaviour in and around the pharmacy.
It is essential that the pharmacist should be friendly, supportive and understanding,
and should administer the drug in a discrete area, preferably at a quiet time. The needs
of other patients and customers should also be considered.
To ensure effective supervised consumption of methadone and minimum disturbance
to the pharmacy, the Glasgow guidelines recommended that the pharmacist develop a
contract with the patient. This was intended to cover key issues such as the time the
dose may be collected; arrangements for when the pharmacy is closed; the need for the
patient to have a legally signed prescription; procedures governing missed doses and
the consequences of unacceptable behaviour in the pharmacy.
The guidelines also suggest that the dose of methadone should be ready and waiting
for the patient. The service should be discrete and efficient, there should be full
adherence to the requirements of the medicines act and the pharmacist should be
convinced that the dose has actually been swallowed – usually by providing a drink
and then talking with the patient.25 To facilitate the monitoring process, it is also
important for the pharmacist to build a relationship of trust with the patient.
Since 2002 the Health Board has paid pharmacists a retainer of £102.50 per month
plus a £2.02 dispensing fee. The pharmacy received 60p per supervision if it was open
five days a week and 81p per supervision if it is open six or seven days a week.
Participating pharmacists were, in return, required to take part in clinical audits and
training, and to submit activity reports.26
Pharmacy needle and syringe exchange schemes in Glasgow
In April 2002, 15 Glasgow-based pharmacies were participating in the free needle and
syringe exchange service and issued 468,738 needles/syringes. Under the terms of the
Scottish Drug Tariff27 participating pharmacists are required to:
· supply needles, syringes and equipment for safe disposal free of charge to drug
users;
· receive used equipment for safe disposal from drug users, normally in
exchange for new needles and syringes;
· provide advice to injecting drug users after suitable training;
· keep a record of transactions;
· complete a self-study course on the administration of this service.28
Participating pharmacists are paid an annual fee for offering this service and a fee per
exchange.
25 Roberts, 2000.
26 Roberts, 2000.
27 Scottish Executive, 2001.
28 Scottish Centre for Pharmacy Postgraduate Education, 1999.
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Training and support for community pharmacy in drug misuse
The Audit Commission29 argued for an even greater role for pharmacists in drug use
services. It has been suggested that the full range of training requirements for
pharmacists to fulfil this demanding role needs to be addressed. To this end, a number
of developments in education have taken place in Scotland:
· Through the University of Strathclyde/Greater Glasgow Health Board
Academic Pharmacy Practice Unit, 107 pharmacists have completed an
accredited health promotion training programme.
· The Scottish Centre for Pharmacy Postgraduate Education has provided
continuing education for pharmacists on drug use and the treatment of opiate
dependence.
· All pharmacists participating in the needle/syringe exchange scheme must
complete the Scottish Centre for Pharmacy Postgraduate Education package
‘Needle and Syringe Exchange Schemes in Community Pharmacy Practice’.
· Completion of the Scottish Centre for Pharmacy Postgraduate Education
package ‘Pharmaceutical Aspects of Methadone Prescribing’ is now a
requirement for Glasgow pharmacists entering the contracted methadone
programme.
· Joint education meetings are held for general practitioners and pharmacists
involved in the methadone prescribing and dispensing programme to discuss
matters of common interest.
The Greater Glasgow Health Board now also employs a Pharmaceutical Policy
Adviser to provide professional guidance and develop strategies to meet the
pharmaceutical care needs of the population. Furthermore, in 1996, the Greater
Glasgow Health Board appointed an Area Pharmacy Specialist – drug abuse worker,
which was a senior pharmacist with responsibility for planning, development and
implementation of pharmaceutical services for drug misuse and harm minimisation.
Funding has been obtained for a peripatetic pharmacist to work with participating
pharmacists on making links between community pharmacy and social work
departments, to provide locum cover for pharmacists attending case conferences and
to support pharmacists in their work with drug users.
The Scottish Executive has offered funding for the construction of specific areas in
Glasgow and Lothian pharmacies to allow methadone consumption to take place in
private and away from other customers. This initiative has come about in response to
the concerns of patients who did not want to be seen consuming methadone on local
pharmacy premises.
Funding has also been secured for Eppendorf Varispenser®30 pumps to dispense
methadone, for additional controlled drug cabinets for high activity pharmacies and
29 Audit Commission, 2002.
30 The Eppendorf Varispenser® is a bottle-top dispenser designed for taking aliquots of liquid from
large supply bottles that ensures exact reproducible dispensing and protects the user.
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for CCTV cameras in needle and syringe exchange pharmacies and pharmacies with
high levels of supervised consumption of methadone activity.
Finally, a Pharmacy Methadone Advisory Group has been set-up. This is a
multidisciplinary group consisting of social workers, the Drug Action Team co-
ordinator, the Director of Public Health, Glasgow Drug Problem Service,
psychiatrists, a GP facilitator and pharmacists. Its aim is to drive forward the
involvement of pharmacy in drug misuse.
Interviews with stakeholders
Introduction
Seven qualitative interviews with key stakeholders in the Glasgow drug misuse
services were conducted – three with pharmacists participating in the SCM service,
one with a pharmacy manager and three with individuals involved at a strategic level
with the development of drug use services. The interviews aimed to explore the
perspectives of stakeholders and those participating in these services, and also to
discuss the scope for future initiatives in pharmacy. With one exception, interviews
with participants were tape-recorded and transcribed.31 Information about the identity
of the interviewees is withheld to protect confidentiality.
General views of stakeholders and participants regarding pharmacy involvement in
drug use services
All of those interviewed were generally positive about the involvement of pharmacists
in the provision of services to drug users. Widespread recognition of the public health
and street crime issues associated with illegal drug injecting, coupled with the
innovative approach adopted by the Greater Glasgow Health Board and other partner
agencies, were motivating factors for pharmacists. Participating pharmacists noted
that they had an opportunity to exercise both their clinical and communication skills,
receive remuneration for the service and have an impact on a major public health
problem.
One stakeholder noted that pharmacist participation in SCM tended to be much higher
than for needle/syringe exchange schemes because pharmacists felt more in control of
the service and because users who decided to embark on substitution therapy were less
likely to be troublesome to staff and other customers.
Several participants commented on the advantages of having pharmacists provide a
monitoring and supervision role for methadone therapy. These included the fact that
pharmacies are positioned in the local community, with straightforward access to
areas in which drug users live and the fact that the non-specialist nature of pharmacies
helped reduce the stigma of drug use. Others commented on the importance of
building a relationship with patients.
31 One participant asked not to be recorded so verbatim notes were taken of the interview.
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“You can tell from day-to-day what they’re doing, and you get an idea if
they’ve been taking street drugs as well by the pallor of their skin and their
eyes. Once you know them it’s possible to ask them if they’re OK, or if they
need anything else. It’s not just about making sure they take their methadone
and getting them out of the shop.” [Pharmacist 1]
It was noted that pharmacists involved in SCM could act both as patient advocate and
provider of a health service through their position in the local community. They could
play an important linking and mediating role with local prescribers through their day-
to-day knowledge of drug users. One stakeholder gave the following example:
“A GP might decide to strike off a patient, for whatever reason. It’s possible
for me to intervene. The pharmacist can act as a sympathetic ear, because we
have the inside knowledge of what’s going on in the patient’s life.”
[Stakeholder 2]
The development of linkages and partnership working between different professionals
– GPs, specialist drug teams, social work and pharmacy – was held up as one of the
key benefits of the service, and one that had had helped to reduce the traditional policy
isolation of community pharmacists. Furthermore, the involvement of individuals
from the Scottish Centre for Pharmacy Postgraduate Education and professionals from
specialist drug teams in training pharmacists had helped the service succeed.
Occasional problems with users coming into the pharmacy at times when it had not
been agreed that they should attend for their methadone dose were mentioned.
However, such incidents were relatively infrequent. Of greater concern was the impact
of the numbers of drug users attending for their daily dose of methadone on other
customers. One stakeholder commented that where activity in relation to the supply of
methadone was particularly high, there were simply too many drug users entering the
pharmacy. One stakeholder also commented that there were not enough pharmacies
providing needle and syringe exchange schemes. Furthermore, the lack of a discrete
or quiet area to carry out supervised consumption in some pharmacies could be
embarrassing for both drug users and customers alike, particularly after the users had
become stabilised on substitution therapy. This was recognised as an issue, and in
response local health boards are funding the creation of private consultation areas, but
it still remains an acute problem for some pharmacies.
In accounting for the success of the service in Glasgow, one stakeholder commented
that the size of the problem and the significance of drug use as a public health,
criminal disorder and economic problem had stimulated funding for the service. The
commitment of other partner health professionals to multidisciplinary working and to
engaging with the social care agenda had also facilitated success.
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Case study One: Summary of findings and lessons for future initiatives
1. Multi-agency networking, particularly the involvement of the Glasgow Area
Pharmaceutical Committee in the Glasgow Drug Problem Service was an
appropriate forum for addressing local priorities.
2. The commitment of other health professionals to multidisciplinary working and
the social care agenda were key factors.
3. The development of linkages and partnership working among different
professionals – GPs, specialist drug teams, social workers and pharmacists – were
the real key benefits of the service, and helped reduce the traditional isolation of
community pharmacy services.
4. Community pharmacy has shown that it can use its position as a community based
health provider to improve access to drug use services. The fact that pharmacies
are located at the heart of local communities facilitated the successful spread of
the service. The unique combination of local accessibility and referral contacts that
community pharmacists offer was a crucial factor in determining the success of
this initiative. And a benefit that could be used to advantage for other health
improvement initiatives.
5. The support available from pharmacists working in strategic positions, for
example, as Pharmaceutical Policy Advisers, Area Pharmacy Specialists and Drug
Abuse workers could be vital to the pharmacists offering the service.
6. Evaluation research, audit, the development of clear guidelines and service
contracts with the commissioning agencies helped to achieve successful outcomes.
7. The use of a written patient contract and the provision of a private consultation
area in the pharmacy were also important to establish so that both the pharmacist
and the user found the level of support acceptable.
8. The importance of the environment in which the consultation between pharmacist
and user was made was extremely important – both in physical as well as
behavioural/psychological terms. This had to meet the needs of both user and
pharmacist as well as the pharmacist’s professional needs. The physical
environment needs to provide enough privacy and confidentiality for both parties
to feel comfortable. That may not simply be a matter of being overheard but being
identified as using the pharmacy services, whether visually or by conversations
with third parties. This is particularly the case when clients are receiving
particularly sensitive services that carry moral and social stigma. There is also a
need to develop a credible relationship between the pharmacist and the client. NB
this may apply to the pharmacy staff as well as the pharmacist. Ideally the
relationship will be based on trust, centred around the needs of the client and built-
up over a period of time to ensure a long-term relationship. When this is not
possible, either because the relationship is short-term and/or there are professional
difficulties in establishing trust with the client, then this service should be made
available in written form and could be a by providing a pharmacy leaflet or
supportive computer print-out.
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Sexual health and pregnancy – 31 projects
Over two-thirds (21) of the projects identified involved the supply of emergency
hormonal contraception (EHC) by pharmacists under Patient Group Directions. Most
schemes aimed to reduce teenage pregnancy as part of local sexual health strategies.
Outcome measures were primarily client numbers.
EHC provision schemes were generally developed through local collaborations with
family planning and sexual health services such as the Brook Advisory Service. In the
Coventry area, a sexual health project was developed in partnership with local youth
services, school nursing and health promotion services to provide free pregnancy tests
for under-19-year-olds and to link young women to the appropriate services on
receiving the results.
Other projects included:
 Information and encouragement for women to take up cervical screening services
in Redbridge and Waltham Forest and Barking and Havering.
 In Enfield and Haringey pharmacists ran a Chlamydia Awareness Campaign
including leaflet distribution and an anonymous self-test quiz.
 The use of community pharmacies as an information and advice point about
contraception for young women.
 Free pregnancy testing, free condom provision in Coventry and opportunistic
encouragement to use local family planning services in Rotherham.
 ‘Folic Acid and Pregnancy Awareness Week’ campaign
 More general campaigns to raise awareness of sexual health issues and to promote
the use of local services.
Participating pharmacists were usually required to undergo training. In Manchester
Salford and Trafford EHC services (see Case Study 2), included training in both
clinical knowledge and communication skills from family planning experts. Payment
was generally per consultation.
Problems that emerged with existing schemes included difficulties with providing
quiet consultation areas and with remuneration policies (some employers expect
pharmacists to provide the service as part of their ‘normal’ duties, while others pay
them a proportion of the fee). There were also problems with lack of time and
resources in pharmacies with a high number of EHC clients – for example, one central
Manchester store had to deal with around 20-30 requests for EHC every Monday
lunchtime.
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Case Study Two: Pharmacy supply of emergency hormonal contraception (EHC)
in Manchester, Salford and Trafford Health Action Zone.
Introduction and background
Community pharmacy supply of EHC via Patient Group Directions is an extremely
important public health service.32 Initiated in December 1999 within the Manchester,
Salford and Trafford Health Action Zone to try to combat the very high rates of
unwanted pregnancy among young people, the service involved community
pharmacists supplying EHC, while also providing a range of complementary sexual
health services.
Policy context
The UK has higher teenage pregnancy rates than much of Western Europe.33 The
Government White Paper Our Healthier Nation (1998) and the report from the Social
Exclusion Unit34 identified this area as a priority, given the adverse health and social
consequences associated with teenage and unwanted pregnancy. In particular, the
strong association in the UK between socio-economic deprivation and teenage
pregnancy suggests that interventions need to be targeted at deprived areas.35 The
provision of EHC in pharmacies has long been advocated as one method for
addressing high teenage and unwanted pregnancy rates in relatively deprived areas.36
Rationale for the development of the service
Evidence suggests that women’s use of EHC may be influenced by difficulties in
obtaining it.37 In particular, teenagers’ concerns about confidentiality and disclosure
may prevent them from asking for EHC from GPs.38 Some women also lack the
confidence to access the ‘health system’ and make an appointment.39 Young women
also may not know about family planning clinics, and even those who do may think
that services are not available early in the week or over the weekend – the time when
EHC is most often requested.40 In short, research suggests that traditional suppliers of
EHC may not be meeting the needs of their patient group (teenagers in particular), and
that widening access to EHC may have an important impact on teenage and unwanted
pregnancies.
The campaign for a community pharmacy-based emergency hormonal contraception
service was based on the fact that:
 Community pharmacists are the most accessible of all primary healthcare service
providers and no appointment is required.
 An existing network of service providers covers extended opening hours including
Sundays.
32 O’Brien & Gray, 2000; Seston, 2000
33 McLeod, 2001
34 Social Exclusion Unit Teenage Pregnancy 1999
35 McLeod, 2001
36 Glasier, 1993
37 Ellertson et al., 2000
38 Hadley, 1995
39 Ellertson et al., 2000
40 Ellertson et al., 2000
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 Young people can access community pharmacies without fear of their parents
being informed.
 Pharmacies in high street locations can be easily accessed by public transport.
Development of the Manchester, Salford and Trafford Health Action Zone
emergency hormonal contraception service
The successful award of Health Action Zone status to Manchester, Salford and
Trafford proved an essential catalyst for the development of the pharmacy-based
emergency hormonal contraception service, providing the necessary funding,
organisational and political commitment for innovative service developments. Set-up
in 1997, the remit of the Health Action Zone was to find innovative ways to tackle
inequalities in health and health service provision. The incorporation of community
pharmacy into the work of the Health Action Zone was initiated by representatives
from the Local Pharmaceutical Committees This led to the formation of the Pharmacy
Partnerships group – a steering group consisting of Local Pharmaceutical Committee
members, Pharmaceutical Advisers and, later, pharmacists from secondary care.
Project managers
The appointment of two project managers funded to work with the Pharmacy
Partnerships group was crucial to the development of the Health Action Zone
emergency hormonal contraception service. One was funded by the RPSGB’s
Pharmacy In A New Age initiative and the other by Manchester Health Authority.
Documentary analysis and interviews with stakeholders suggest that the leadership
and vision of the project managers, working alongside pharmacy partnerships, formed
the basis of a cohesive pharmacy development group, able to promote community
pharmacy in relation to the Health Action Zone’s agenda.41
Patient group directions
Legal advisers confirmed the possibility for pharmacists to become involved in
supplying emergency hormonal contraception (EHC) under a group prescribing
protocol. Key considerations for the acceptability of the use of the group protocol for
EHC were:
 Selective training and accreditation of professionals providing the service.
 Consideration of community pharmacy premises as self-contained ‘clinics’.
 A protocol pro forma enabling the pharmacist and client to check
understanding and to sign an agreement during the initial consultation.
 The support of a group of clinicians who accepted responsibility for the
protocol.
 Patient information leaflets.
 Audit.
41 O’ Brien & Gray, 2000; Anderson et al., 2001
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The Pharmacy Partnerships steering group believed the way forward was to supply
EHC42 under a group protocol. It was argued that this would provide a number of
benefits:
 It would demonstrate a new way of providing medicines related services for
pharmacists.
 It would reinforce the notion that the EHC provided was not an item of
commerce.
 The protocol would require and structure personal interaction between the
pharmacists and their clients.
 Pharmacists could be paid for their professional skill in history taking and
providing appropriate advice regardless of supply.
 The service could be audited via detailed record keeping using the protocol pro
forma specific to each consultation.
A senior family planning doctor and health professionals who had worked on the
development of nurse prescribing protocols constructed the group protocol for use by
community pharmacy. The involvement of a senior family planning doctor provided
the key impetus for the development of the service. Early on, the Patient Group
Directions had no firm legal foundation for use within community pharmacies.
However, protocols were developed for use with combined oestrogen and progestogen
EHC and later with progestogen-only EHC.43 By August 2000, the Department of
Health had issued guidance in this area44 and the legal foundation for Patient Group
Directions to be used by pharmacists was established.
Patient Group Directions are group prescribing protocols that give suitably trained and
accredited pharmacists the legal authority to supply prescription only medicine to
requesting clients. In this case, the Patient Group Directions establishes that EHC
should be supplied free of charge and can be supplied to girls under the age of 16 if
the pharmacist considers it appropriate. The development of the Patient Group
Directions was a lengthy process supported by a specification outlining the project’s
aims, objectives and audit standards to be applied. The project support materials
included: pro forma assessment sheets and medical record sheets, data monitoring
forms, payment claims forms, locum payment claim forms, guidelines on
documentation, emergency clinical contact sheets, referral forms, accreditation
certificates and lists of other local health services. A telephone support system made
clinical advice and information from local family planning doctors available to
pharmacists. A local branch meeting of pharmacists in Manchester, Salford and
Trafford also provided an opportunity to discuss the expected problems and solutions
with the service.
42 In this case, Schering PC4.
43 Levonelle-2 became available as an over-the-counter product in January 2001 as a result of a
successful application by manufacturers Schering Healthcare for a pharmacy product license. It retails
at a cost of £24. As a result, both the over-the-counter product and the Patient Group Directions
schemes operate side-by-side in some areas.
44 Health Service Circular 026 (2000). London: Department of Health. Available online:
www.info.doh.gov.uk/doh/coin4.nsf/circulars.
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A group of local doctors and managers signed the group protocol to authorise
accredited pharmacists within the Health Action Zone to supply EHC. The pharmacist
and the client work through each stage of the protocol and both parties are required to
sign each section of the protocol pro forma to confirm understanding.
Recruitment and training of pharmacists
Once the appropriate project support material had been prepared, it was necessary to
recruit a cohort of community pharmacists to supply. Interviews with stakeholders
demonstrate that there was a commitment to recruit pharmacists who would provide a
non-judgmental and empathic service to users. In late 1999, two community
pharmacies per primary care organisation were selected for the service. Pharmacists
underwent training and skills enhancement programmes incorporating clinical and
communication skills appropriate to supplying emergency hormonal contraception.
Training was mainly provided by local family planning doctors and the Centre for
Pharmacy Postgraduate Education. ‘Role-play’ was included in all the programmes
and was designed to cover situations about which pharmacists were most concerned –
as determined from early discussions. Evidence from evaluations indicates that the
‘role-play’ scenarios were extremely useful and equipped pharmacists with the social
and communication skills necessary for dealing with sensitive issues.45
In 2002 the service was available at over 120 pharmacies within the Manchester,
Salford and Trafford area.
Brief service description
After completing the training programme, pharmacists were permitted to supply
emergency hormonal contraception to requesting users free of charge following a
thorough consultation. The pharmacist had to adhere to the Patient Group Directions
protocol, which guided their decision about whether to supply EHC. If the pharmacist
was unsure about whether to supply, local family planning doctors offered back up.
The service was confidential and anonymous, and no records that could identify the
requesting user were kept, although the pharmacist did record the client’s postcode for
data-monitoring purposes. The pharmacist recorded basic details of the consultation
separately on a pro forma audit sheet.
Consultations with clients were expected to take place in a private area. From its
outset, the scheme was designed as a sexual health service, rather than simply the
provision of emergency hormonal contraception. Pharmacists recorded the reason for
requiring emergency hormonal contraception (e.g. unprotected sexual intercourse,
missed contraceptive pill, broken condom), provided verbal and written information
on contraception and sexually transmitted infections, and offered sources of further
advice and information. They also provided counselling about the possible risks and
the side effects of EHC and some provided free condoms with the EHC supply.
In Manchester, the protocol indicated that clients should be asked to take the first of
the two pills in store. Pharmacists received a payment of £10 per consultation.
45 Anderson et al. 2001 a,b.
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Evaluation of the service
Researchers from the School of Pharmacy at University of Nottingham researchers
carried out an independent evaluation of the service.46 In Manchester, Salford and
Trafford, some 13,256 women accessed the service between 24 December 1999 and
31 March 2001 and 93% of these were supplied with EHC. Of those women, only
28% were aged under-19 years.
Independent evaluations showed that users expressed high levels of satisfaction with
the service - 99% of users in Manchester, Salford and Trafford were ‘very satisfied’ or
‘satisfied’. Over 95% of users stated they had received sufficient information about
EHC from the pharmacist and over 90% suggested that they felt comfortable talking to
the pharmacists about EHC. Just over three-quarters felt there was sufficient privacy
in the pharmacy. However, approximately one-fifth of users had concerns about the
confidentiality of their request.47
The evaluation showed that pharmacists were also extremely positive about the
service.48 Pharmacists commented that they believed they were providing an important
service for users that allowed them to use their clinical and communication skills
which was also professionally rewarding.
Key Findings and lessons for future development
1. Successful award of Health Action Zone status to Manchester, Salford and
Trafford; funding against political commitment. Development of local objectives
for reducing health inequalities in five areas (children, young people, active senior
citizens, mental health, community capacity building). Funding and focus on
health improvement.
2. Development of local organisational structure (Local Pharmaceutical Committees
and Pharmacy Partnerships group) and appointment of Project Managers providing
basis for leadership, promotion of community pharmacy agenda and networking
with Health Action Zone.
3. ‘Brainstorming’ of Health Action Zone local objectives by Local Pharmaceutical
Committees and production of 13 potential service options for community
pharmacy.
4. Questionnaire consultation process with community pharmacy contractors on
potential service options: ensured pharmacist support, despite 33% questionnaire
response rate.
5. Project managers liaise with Health Action Zone Director - reducing teenage
pregnancy and medicines review selected as pharmacy priorities.
6. Project mangers liaise with family planning doctors and Brook Advisory services
– ensured multi-agency support for reducing teenage pregnancy.
7. Development of Patient Group Direction protocol and related administrative
infrastructure by project managers, with support from legal advisers, family
planning doctors and other health professionals.
46 Anderson et al., 2001a,b.
47 Anderson et al., 2001a,b.
48 Anderson et al., 2001a,b; Savage, 2001.
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8. Development of pharmacist clinical and communication skills training in
conjunction with Centre for Pharmacy Postgraduate Education, family planning
doctors and Brook representatives.
9. Selection of pharmacies in each primary care organisation for involvement in pre-
millennium launch.
10. Launch.
11. Audit and evaluation of project.
Interviews with stakeholders
Introduction
A series of qualitative interviews were carried out with key stakeholders involved in
the Manchester, Salford and Trafford community pharmacy emergency hormonal
contraception project and public health officials working in the local area. The
interviews explored stakeholder perspectives in relation to the community pharmacy
EHC service and focused on the scope for future health improvement initiatives.
Interviews with participants were recorded and transcribed. Information about the
identity of the interviewees is withheld to protect confidentiality.
Perspectives on the community pharmacy emergency hormonal contraception
service
Assessments of community pharmacy involvement in emergency hormonal
contraception provision were overwhelmingly positive and underline the perception
that this was a successful initiative with clear benefits for clients, pharmacists and the
Health Action Zone.49
“It’s been a milestone for pharmacy. Not only has it increased pharmacists
confidence in delivering an innovative service for women . . .but in the process
it has also changed women’s ideas about community pharmacy.” [Stakeholder
1]
Stakeholders highlighted the following advantages for service users:
 Women had improved access to emergency hormonal contraception because a
broad network of pharmacies provided a dispensing service at a range of
appropriate times.
 The service was free and provided in an area with high rates of teenage and
unwanted pregnancy, thereby meeting the Health Action Zone requirement that
services should have an impact on inequalities in service provision.
 The service required no appointment, was completely confidential, and also
involved an assessment of the individual’s contraceptive and sexual health needs
49 These findings replicate those noted by Anderson et al. (2001a,b) and Savage (2001) in their
evaluations of the community pharmacy EHC services for Manchester, Salford and Trafford, and
Lambeth, Southwark and Lewisham HAZs.
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 There was the option of referrals to other health professionals and a health
promotion component (distribution of condoms and leaflets for STI services and
provision of counselling around contraception where appropriate).
Stakeholders also noted that the service was extremely popular with pharmacists.
Advantages for pharmacists included:
 The professional satisfaction of providing a service that addressed both the Health
Action Zone agenda and the needs of women clients, whilst also exercising
pharmacists’ clinical and communication skills.
“Doing the right thing, is personally the motivation . . . pharmacists are for
ever saying that they want to get involved, they’ve got the skills but they’re
under-used . . . Here, pharmacists applied their skills and used their
knowledge base…plus they were paid to do so.” [Stakeholder 3]
The successful implementation and operation of the service highlighted the important
contribution community pharmacy could make to reducing inequalities in sexual
health service provision and having an impact on unwanted pregnancies.
Reasons identified for the success of the emergency hormonal contraception service
Stakeholders were asked to account for the success of the emergency hormonal
contraception service. In addition to the benefits of addressing the Health Action
Zone’s agenda, client need and the agenda of the pharmacy profession, stakeholders
also identified a number of organisational factors that, in their view, accounted for the
success of the service. Above all, the award of Health Action Zone status provided the
organisational scope and financial resources for the service development.
A number of stakeholders referred to the important leadership role played by the
project managers in overcoming the administrative and organisational obstacles (such
as the uncertain legality of the service) and in taking risks and proving leadership for a
project that might otherwise have floundered.
Other stakeholders referred to the importance of the Local Pharmaceutical Committee
and the Pharmacy Partnerships group as a pharmacy development forum that assisted
the success of the project, and to the importance of a body of committed pharmacy
contractors willing to get involved in an innovative service.
The importance of multi-agency working and support for the development of the
project, training of pharmacists and the provision of clinical back up was also
highlighted as crucial for successful development. In particular, the support of local
family planning doctors, the Brook Advisory service and individuals working on the
local medical committee were viewed as important to the project’s successful
development.
Disadvantages and drawbacks of the service
Administrative and organisational drawbacks to the EHC service - noted by
stakeholders - included delays in receiving payment for the service and problems with
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pharmacists choosing not to supply EHC on moral or ethical grounds. Some women
also viewed the protocol requirement to take the product in-store as unnecessary and
irritating. However, these were generally of concern to a minority of people.
Of greater concern to participants was the impact of the EHC service on mainstream
public health issues, such as sexual health and STIs. Interviewees were concerned that
EHC might be used as a regular form of contraception instead of a client’s usual
method, or would encourage the client not to bother to use her usual method and this
might have an impact on STIs. However, there was no strong evidence for this
concern, and one participant noted that the British Medical Association was strongly
in favour of the service and did not believe there was evidence of a link with STIs.
Stakeholders also highlighted the fact that, from the start, the Patient Group Directions
protocol had emphasised that this was a sexual health service, rather than simply a
means to obtain emergency hormonal contraception.
“Of course, I think we’ve got to be concerned about sexually transmitted
diseases and rates of unprotected sex, which is why we specifically built a
referral element into the protocol. We are providing a sexual health
service.”[Stakeholder 1]
Other stakeholders were more trenchant, suggesting that it was important to have
some faith in the common sense of the women who were accessing the service and
that, on a simple risk-benefit assessment, it was surely an advantage that women were
accessing the service at all.
“What I think we’ve got to accept is that women are actually choosing to come
to the pharmacy (for whatever reason), rather than risking a pregnancy. This
is got to be preferable to them doing nothing, and perhaps having an
unwanted baby.” [Stakeholder 6]
Although generally positive about the project, one stakeholder - commenting on the
audit data that showed that only around one-fifth of users were aged 19 years or under
- questioned whether the service was having the impact that the Health Action Zone
desired on inequalities in rates of teenage and unwanted pregnancies.
“Of course, it’s a success in the sense that it’s up and running, pharmacists
are taking part, more and more women are using it and it’s viewed very
positively. But with my public health hat on, I don’t know if this is having the
effect we wanted. Is it simply the well off, and educated women using it, or are
we reaching everyone?” (Stakeholder 6]
The future for community pharmacy: a continued role in improving health and
reducing inequalities
An important component of the interviews centred on discussing with stakeholders the
scope for future work on public health and health inequalities.
In general, the pharmacy stakeholders were extremely positive about the potential for
future pharmacy involvement in public health initiatives. Stakeholders noted that the
EHC project demonstrated the effectiveness of the Patient Group Directions route for
Final Report 2005
28
the supply of medication related services and that the key advantage of using
pharmacy was access to services. It was suggested that the Patient Group Directions
supply model could be extended for other services such as nicotine replacement
therapy and treatment for eye infections.
“Personally, I don’t see why we shouldn’t be able to supply nicotine
replacement therapy using a protocol, or some other means. Pharmacy is
opportunistic, isn’t it? The customers pass by, see nicotine replacement
therapy in the window and think about giving up smoking. Now, between
thinking about it and going to the general practitioner or your practice nurse,
time has passed. But they might just come into the pharmacy and if it’s free . .
there is potential there I think.” [Stakeholder 5]
Positive comments were also received about pharmacy involvement in developing
innovative services for drug users such as the supervised dispensing of methadone and
the provision of needle syringe exchange schemes. These services were expanded to
capitalise successfully on pharmacy as a locally accessible health provider.
Some stakeholders referred to the development of health promotion, although one
stakeholder noted that health promotion should be seen as a specialist activity, not
simply as an ‘add-on’ service taken up by all pharmacists. Others referred to the wider
public health agenda and the role pharmacy could play in relation to that. One
stakeholder noted:
“The public health agenda is currently immense, and there is a major
potential for pharmacy to get more involved. Pharmacists see ‘well’ people in
addition to the ill. There’s major opportunities for leaflets. . . I think things
like diagnostic testing, early identification of diabetes, blood pressure
monitoring, primary prevention and identification of disease as well. The
whole area is massive, and as yet, unexplored.” [Stakeholder 1].
The links between early diagnosis/disease identification, the local nature of pharmacy
and the fact that pharmacy sees both the well and the ill was often highlighted. One
stakeholder asserted that in order to develop such services community pharmacy
would need to think strategically about how to galvanise innovation and change within
the profession:
“The Health Action Zone service worked because there was money to develop
the services and pharmacists got paid for a service they enjoyed doing.
[Stakeholder 4]
It was also pointed out that two-thirds of all community pharmacists were in fact
employees and the individual scope for taking part in innovative public health
initiatives was relatively limited. It was suggested that the crucial links would be with
the larger chains and supermarket pharmacies, which would determine future policy.
Finally, a number of stakeholders referred to the medicines management pilot schemes
taking place in the UK and the potential public health impact that these might offer.
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The non-pharmacy stakeholder was less enthusiastic about the future contribution of
pharmacy in public health and considered pharmacy – and other health services – to be
able to play only a limited role in reducing health inequalities.
“It’s difficult for me to see where public health and pharmacy actually
coincide. Yes, I can see that the EHC project worked in Salford and Trafford
and I can see stop smoking services as a way of reducing health inequalities –-
same with methadone. These are public health issues where pharmacy can
make a difference…but as a public health specialist taking a social model of
health, I’m not sure where else we can go with this.” [Stakeholder two]
In the face of such views, pharmacy may need to think about its connections with the
wider public health and health inequality agenda. The arguments raised by this
stakeholder highlight a potential tension between a social model of health and one that
seeks to provide general health services and pharmacy policy makers may need to
address this.
Accident prevention – 7 projects
These projects focused on preventing falls in older people (including promoting bone
health and osteoporosis prevention) and child accident prevention (including
accidental poisoning). Their main intentions were to give information and to raise
awareness. No precise outcome measures were given.
Innovative examples of service provision
UK:
Some projects provided brief training sessions. In Enfield and Haringey, a community
pharmacist, a physician specialising in medicine for older people, a physiotherapist
and a primary care manager provided training.
International:
In Sweden 13, community pharmacists ran osteoporosis groups in conjunction with the
national ‘sports for all’ association. These targeted women aged 45-60 and aimed to
increase physical activity and healthy eating, and provide smoking cessation support.
There was a charge to join but in many areas local councils covered some of the costs.
A training day was held for pharmacists and ‘sports for all’ staff. Participating women
were given a book and asked to prepare for each meeting by reading a section. The
programme involved 14 weeks of biweekly seminars on lifestyle and physical
activities. It was evaluated through the women’s self-reports of changes. Participants
reported that their sense of wellbeing increased, their strength and balance were
improved, and they spent more time outdoors and had improved their diet.
In Finland 13, a programme was set up for pharmacies to provide information about
the risks inherent in combining medicine and alcohol, and about the appropriate use of
medicines. The Finnish Pharmaceutical Society provided window display materials
and public information leaflets. Two television public information slots were also
provided. A press conference generated substantial local and national publicity for the
scheme, and individual pharmacies also held local events. Pharmacists gave over 400
lessons to 13 to 15-year-olds in schools, using materials produced for the project.
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Health screening, coronary heart disease and diabetes – 12 projects
Of the health screening projects identified, most involved the identification of high-
risk patients from pharmacy medication records, through prescriptions presented and
on the basis of over-the-counter purchases. Identification was followed by the
provision of advice and information. Indicators for coronary heart disease included the
purchase of low-dose aspirin and the presentation of prescriptions for cardiovascular
medicines. Two areas reported diabetes initiatives, both of which were short-term and
focused on information provision to high-risk groups identified in a number of
different ways including patient medication records, over-the-counter purchases and
health advice requests.
Innovative examples of service provision
UK:
In Bedfordshire, where pharmacists identified patients at risk of diabetic eye problems
and glaucoma, participating pharmacies were paid for each referral made to local
optometrists (with whom the scheme was developed). No other remuneration
information was available.
One project based in Harrow, North London, incorporated an evening of training
based on the CHD National Service Framework.50 Little specific detail of training was
given for other screening projects reported through the survey, although all mentioned
some form of training.
International:
The Institute for Clinical Pharmacy, University of Basel, Switzerland developed a
model for diabetes screening based on existing literature and advice from diabetes and
public health experts. This was piloted in two community pharmacies. A triage flow
chart was produced to guide pharmacists’ testing and referring clients. People with
two or more risk factors were offered a blood glucose test (fasting if possible;
otherwise values above 5.3 mmol/l prompted a second test in the fasting state).
Counselling about risk factors was based on the trans-theoretical model of behaviour
change. The Toppharm group of 60 pharmacies piloted the campaign for four weeks
in 2000. Of 704 people screened, 7 were found to have insulin dependent diabetes
mellitus and 71 non-insulin dependent diabetes mellitus. The model will be further
evaluated in a national campaign involving 600 community pharmacies.
In Australia there are plans to involve community pharmacists in primary and
secondary diabetes prevention. Based on feasibility studies with 470 community
pharmacies in Western Australia, these schemes are likely to focus on
anthropomorphic testing (waist and adiposity) measurements, with wider risk factor
assessment taking into account age, gender, smoking status and ethnicity. This
approach has been shown to be as meaningful as, but less complicated and invasive
50 Pharmaceutical Journal 10 Nov 2001.
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than, the testing of other indicators such as cholesterol, blood glucose or glycosylated
haemoglobin.51
Another major Australian initiative aimed to establish and evaluate a service whereby
community pharmacists assessed clients’ needs for health information, screening tests
and referral. The initial focus was on cardiovascular disease and its risk factors
(hypertension, hyperlipidaemia, diabetes, smoking and obesity). The service model
developed for this disease was intended to provide a template for other diseases such
as cervical cancer (e.g. referral for pap smears) and infectious childhood diseases (e.g.
referral for immunisation).52
Obesity and weight management – 3 projects
The projects on obesity reported were linked to prescribing guidelines for Orlistat.
Innovative example of service provision
UK:
The evaluation of a Bedfordshire Lloydspharmacy weight loss programme concluded
that that although there was increased awareness of healthy eating and physical
activity they did not know how sustainable such a scheme would be.
International:
One quarter of Danish community pharmacies 13 offer weight management services on
a group or individual basis. Pharmakon –the Danish College of Pharmacy Practice –
developed the model as part of the Danish Pharmacy Association’s Year of the Heart
in 1999. Pharmacists and their staff underwent two days training and were issued with
an operational manual. Support groups consisted of 10-12 people and were run by a
pharmacist and one or two pharmacy assistants. People attended eight 90-minute
sessions. The service for individuals included five counselling sessions, of which the
first was the longest, with subsequent sessions intended to take 5-10 minutes. No
evaluation of the scheme has yet taken place.
Immunisation – 2 projects
Since this survey was conducted, Grampian area in Scotland has reported on a
pharmacy based immunisation service. Community pharmacists in the Blackpool area
participated in a ‘flu immunisation scheme in which they identified ‘at risk’ patients
and referred them for immunisation. The pharmacists used patient medication records
to target specific therapeutic risk conditions and prescription age exemption to prompt
a discussion with patients. Under the scheme, the pharmacist asked if the patient had
booked a ‘flu immunisation. If not, information was given and a recommendation
made to book an appointment for assessment and immunisation. The community
pharmacists were paid a fee for taking part.53
51 Con Berbatis, personal communication.
52 Ines Krass, personal communication.
53 Magnus Hird, personal communication.
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Grampian Health Board has considered how community pharmacists could contribute
to increasing the uptake of ‘flu immunisations. In 1992-93 two small projects in the
Grampian area demonstrated that community pharmacists could successfully identify
‘at risk’ patients, either systematically by using patient medical records, or
opportunistically when patients made over-the-counter purchases or presented a
prescription for dispensing.54
Innovative example of service provision
International:
In the US, community pharmacists have been administering immunisations for several
years and there are published reviews in the literature.55 Further experience has shown
that community pharmacists, rather than merely acting as an alternative source of
provision, are able to reach a group of patients who have not previously participated in
‘flu immunisation programmes.56
Travel health – 3 projects
Three UK projects on travel health were reported. These included a campaign to
provide advice to travellers and a sun-awareness campaign.
Innovative example of service provision
International:
The Austrian Chamber of Pharmacists 13 worked with the Institute of Tropical
Medicine at the University of Vienna to launch a national campaign focusing on the
use of sunscreen in summer and when travelling abroad in winter. The campaign
offered individual information and counselling combined with information and
advertisements in pharmacy windows. A leaflet and checklist were distributed on
holiday needs and taking medicines abroad. Pharmacists used a computer programme
to advise about immunisation.
Other projects (18)
Other projects reported included campaigns about mental health, parenting, men’s
health awareness, and health promotion aimed at local ethnic groups.
In Sheffield eight pharmacies had touch screen information systems that printed
information about self-help groups and healthy living. In the Croydon area
pharmacists had put up display boards about local authority related topics, e.g.,
cycling to work and keeping warm in winter. Training in health promotion skills had
been provided for counter assistants in the Lothian area in Scotland.
54 Christine Bond, personal communication.
55Anderson, Blenkinsopp & Armstrong (2003).
56 Dale Christensen, personal communication
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Case Study 3: Lloydspharmacy CHAT Centres
Introduction
The development of CHAT (Community and local Health, social and welfare Advice
provided informally by Trained professionals) centres within Lloydspharmacy is
presented as an example of how community pharmacy premises can be adapted to
provide health improvement resources and facilities to the public. The study was
based on using community pharmacy premises as a public health resource and
interviewing a key stakeholder and analysing key documents.
The CHAT centre
The first CHAT centre was set up in Alfreton, Derbyshire, as a result of an
information availability survey commissioned by Derbyshire Health Authorities in
1996. Both the healthy and the ill visit community pharmacies and clients frequently
request advice on social and health care issues. This survey highlighted the lack of
locally available health and welfare-related information.
The aim of the CHAT centre was to provide accessible information and advice,
drawing on the skills of a multidisciplinary set of advisers - from both statutory and
voluntary agencies - in an informal setting. The advisers - including representatives
from Age Concern, Derbyshire Carers, Arthritis Care, social services and the
Derbyshire Centre for Integrated Living, health visitors and district nurses - could be
seen without an appointment and were available on a regular basis. Community
pharmacy was chosen as a suitable venue because of its informal, non-threatening
environment. The centre was particularly intended to provide a sign-posting service on
social issues and concerns.
To augment this, the CHAT centre also provided leaflets and information on a variety
of topics. These included social services, women’s health, childcare, elderly care,
benefits, welfare rights and young adults. Visitors to the pharmacy were encouraged to
take away leaflets and return for verbal advice from an adviser. Advisers were then
able to guide visitors toward further advice if necessary. These general sessions were
supplemented by specialist events, such as osteoporosis awareness, age concern week,
credit unions, your rights and healthy eating.
There are currently nine CHAT centres operating throughout England in Alfreton,
Moss Side (Manchester), Burnley, Sandy (Bedfordshire), Netherton, Christchurch,
Coventry, Clowne and at Lloyds Head Office (Coventry).
Commentary – motivation and reasons for setting up CHAT centres
The CHAT centres - as conceived by Lloydspharmacy - not only provide free health
and welfare resources to customers but have also incorporated a socio-economic
model of health. Whilst they recognise that the additional advisory services will add
value to the baseline services they provide they also:
‘Recognise the broader determinants of health, including the socio-economic
factors and through a Social Pharmacy approach aim to provide an integrated
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package to help local communities make informed social and health
decisions’. [Source: Social Pharmacy, Lloydspharmacy.]
As a key stakeholder explained in an interview, the motivation for this development
emerged from the belief that health was influenced by socio-economic factors and that
pharmacy could play a much greater role in sustaining and developing local health
networks. It was argued that pharmacies are located at the heart of local communities,
are accessible to local community members and, crucially, are able to sustain and
support equality of access for users.
The social pharmacy concept underpinning this vision has led to a number of
networking events and ideas with other statutory and local health and social welfare
providers. Lloydspharmacy are also involved in the development and provision of
Healthy Living Centres and Education Action Zones, and have funded a health
networking conference. They are currently working with the Scarman Trust57 to raise
awareness of their work and to promote health advice and group mentoring, and with
the Jewish population in one pharmacy area to support the use of medicines during the
period of Passover.
The social pharmacy and CHAT centre model adopted by Lloyds represents a highly
interesting and novel approach to public health, particularly with its emphasis on the
wider determinants of health and its focus on social care as much as healthcare. At
present, there has been limited formal evaluation of these initiatives but they merit
further research and evaluation in order to assess their contribution to public health.
Key findings and lessons for future public health initiatives in community
pharmacy
1. The Lloydspharmacy CHAT centres offer an ideal opportunity to find out more
about public responses to a different layout for consultation areas using premises
as a local health resource – particularly relevant given the government’s emphasis
on total privacy.
2. The model highlights the importance of finding appropriate and accurate sources
on which pharmacists can base their advice and information. In this case, the use
of a range of local advisers made an important difference to the quality of
information given out.
3. This in turn highlights the importance of training – both communication and
resource-based – for pharmacists should they be expected to fulfil an information-
providing role.
4. The ready accessibility of community pharmacy and the convenience of being able
to access advice and information resources without making an appointment also
contributed to the success of the project.
5. Economic success? Lloydspharmacy will no doubt evaluate this service in the
future.
57 The Scarman Trust is a national charity committed to helping citizens bring about change in their
community. It funds and gives practical assistance to hundreds of people with a 'can do' attitude.
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Discussion
According to the survey, innovative projects in community pharmacies cover a wide
range of health topics but are highly concentrated in a small number of topic areas.
Just three topics – smoking cessation, sexual health (predominantly emergency
hormonal contraception provision) and drug use – account for 75% of the UK projects
reported. However, the survey response rate was 64% after one reminder and is
therefore likely to underestimate the true level of activity. The Pharmaceutical
Services Negotiating Committee and National Pharmacy Association project
information lists identified a number of additional projects but did not include many
of the projects identified through the survey.
The profile of project activity generally reflected areas in which community
pharmacies can contribute to the achievement of NHS health improvement targets
and, consequently, to reductions in health inequalities. Broad local targets, established
on the basis of national strategies, were adapted to respond to specific local needs and
circumstances.
The activities reported in the UK fall into two broad categories. The first of these
involved direct service provision – usually in the form of treatment for existing
conditions (e.g. smoking cessation, supply of emergency hormonal contraception,
supervised methadone administration). Case Studies 1 and 2 fall into this category.
Such services were developed jointly with the relevant local agencies in primary,
community and secondary care, and the existence of national targets often provided
the impetus for funding. They tended to involve the selection of a sub-sample of
pharmacies to participate, particularly for the introduction of a new service. A targeted
approach was used. In particular, for feasibility studies and for providing coverage of
specific areas on the basis of socio-economic need, or filling a gap in the existing
service provision.
The second category involved the provision of information and advice on specific
health topics. These were usually as a preventative or screening measure and often as
part of a wider local strategy – with the primary objectives of increasing uptake of
other services (e.g. family planning, cervical screening) and raising awareness on
specific health issues (e.g. chlamydia infection). Case study 3 – Lloydspharmacy
CHAT centres – fell into this category, although the centres were considerably more
proactive and readily available than most information services. These projects -
particularly for health information campaigns - tended to invite all community
pharmacies to participate, although they may also have had a pilot phase or targeted
specific areas. Funding for these projects was more difficult to obtain unless they
could form part of a broader public health initiative.
Almost all the projects required the pharmacist to have contact with and impart some
form of advice or information to the patient. Also, certain projects – such as health
screening initiatives – may have begun with information and advice but then involved
into some form of follow-up testing, carried out by the pharmacist. For example,
blood sugar testing for diabetes. The distinction was primarily one of emphasis.
However, it will affect aspects such as the training required for pharmacists to
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participate in, and public acceptance of, the services. It may also affect factors such as
the funding available for services and the willingness of pharmacists to participate.
Location
All these projects take advantage of the exceptionally easy access to health advice
afforded by community pharmacies. The case studies illustrate the vital role pharmacy
can have in improving access to services because of its position as a community-based
health provider. Better access to and local provision of EHC is important because of
the 72-hour time period of effectiveness. Methadone users require a daily dose of their
substitution therapy so services based in local areas facilitate take-up. Information and
services obtained through pharmacies are generally easier to access than having to
make an appointment with a general practitioner. This convenience factor may
encourage users to ask for advice over less pressing but potentially serious health
issues.
The non-pharmacist stakeholders interviewed in Case Study 2 explained how
pharmacy’s contact with both the healthy and the sick allows it a unique role in the
early diagnosis and identification of disease. Public use of community pharmacies is
almost universal and, although use is currently still low for general health advice, it is
higher among women, respondents with young children and lower socio-economic
groups.58 This suggests that pharmacies can make a valuable contribution as an
information source in the quest to combat health inequalities. Community pharmacy
can also fill gaps in service provision from other sources. For example, in the
Calderdale and Kirklees district, a smoking cessation initiative59 aimed to recruit
pharmacies in areas not covered by the existing smoking cessation advisors.
Sensitive Stigmatising / Sensitive Issues
Services providing emergency hormonal contraception and supervised consumption of
methadone may be associated with a degree of stigmatisation and/or sensitivity for
users. This may be exacerbated when the service is provided through specialist
agencies because it is identifiable by location. As a generic health provider,
community pharmacy does not carry the same stigma, although in the Glasgow case
study a high proportion of methadone users did appear to have some concerns about
being judged by other pharmacy users.
This reduction of stigma could apply equally to direct service provision and to advice
giving for sensitive topics. However, concerns about privacy and confidentiality
would have to be addressed first. While most pharmacy users perceive there is
sufficient privacy in the pharmacy to discuss even sensitive subjects,60 around a fifth
of users of emergency hormonal contraception, osteoporosis screening and head lice
management services had some concerns about privacy.61
58 Blenkinsopp, Anderson & Armstrong, (2003). p.41.
59Blenkinsopp, Anderson & Armstrong, (2003). p.35.
61 Blenkinsopp, Anderson & Armstrong, (2003). p.35.
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Consultation Areas
Lloydspharmacy’s CHAT centres have selected a model for consultation areas that
place the user in the centre of the pharmacy. Government recommendations,
meanwhile, in Choosing Health through Pharmacy: A Programme for pharmaceutical
public health 2005-2015 62 - state that under the new contractual framework for
community pharmacy, a consultation area for confidential discussions is required to
provide medicines-use reviews (MURs) advanced services. And some locally
enhanced services will also require private consultation areas or consultation rooms
with additional facilities.
In reality the most appropriate consultation area will depend on the service provided
and probably also on the client accessing the service.
Training
Training was provided for 65% of projects identified by the survey and was often a
prerequisite for pharmacists to be able to provide the service. Both project organisers
and participating pharmacists showed a high degree of commitment to training.
However, respondents often provided little detail about the level and extent of
training, and details of reimbursement schemes for attending pharmacists were given
only in a few cases.
A number of projects mentioned using training material provided by the centrally
funded national Centre for Pharmacy Postgraduate Education, such as their Drug
Misuse programme. Others used training courses prepared by local authorities. It
appears that some project co-ordinators also prepared their own training schemes but
further details were not available.
In addition, the evidence base indicated that most pharmacists would feel more
comfortable providing information on sensitive issues if they had received training.
Particularly training that focused on communication skills and imparting appropriate
information.
Reports 1 and 2 of the evidence base63 make it clear that training - (specifically in
smoking cessation) increased knowledge, self-confidence and positive attitudes of
pharmacists and their staff. In addition, the training needed for pharmacists involved
in drug use programmes included skills in translating technical terms into a more
appropriate language for drug users. Report 2 also noted that the public had a high
desire to access advice on contraception and sexual health from community
pharmacists but rarely asked directly, and pharmacists were reluctant to offer it.64
62Choosing Health through Pharmacy: A Programme for pharmaceutical public health 2005-2015
(Department of Health 2005)
63 Anderson, Blenkinsopp & Armstrong, (2003); Blenkinsopp, Anderson & Armstrong, (2003).
64 Blenkinsopp, Anderson & Armstrong, (2003), pp.16–20.
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Likewise, the RPSGB’s interim report,65 highlighted as key enabling/blocking factors
both the extent to which pharmacies made full use of the skills of their whole practice
team through delegation and training, and also pharmacists’ levels of pro-activity and
confidence in approaching patients and doctors. Active involvement of trained staff
was a common feature among successful projects.66
There was some evidence of multidisciplinary training for the projects identified. This
was important because we found in Report 2 that joint training improved the extent of
sustained joint working between community pharmacists and other members of the
primary healthcare team.67 This was because it helped to break down the traditional
isolation of pharmacists, which was mentioned frequently in the case studies’
stakeholder interviews. The survey showed that smoking cessation training was often
carried out in multidisciplinary groups – a reflection of the projects’ close links with
broader local and national strategies. Training in emergency hormonal contraception
(EHC) provision in Case Study 1 was provided by family planning experts and
covered both clinical knowledge and communication skills. Training for a project in
Coventry to provide free pregnancy tests68 was provided by the Family Planning
Association,69 a trained GP and a teenage pregnancy co-ordinator. Training for an
accident prevention project in Enfield and Haringey70 included input from a
pharmacist, physician, physiotherapist and primary care manager.
Networking / Linking community pharmacists with national and local strategies
Partnership working with other healthcare professionals provided pharmacists with
clinical support and assistance, particularly for the EHC schemes, which were
developed in tandem with GPs and local sexual health service providers. Smoking
cessation services were also developed alongside other providers. In particular, NHS
stop smoking services and GPs. Croydon Local Pharmaceutical Committee worked in
partnership with the local authority to provide information boards on topics such as
keeping warm in winter. Partnership working is, of course, fundamental to the
Lloydspharmacy CHAT centres, which rely on a range of health professionals to
provide advisory services.
Pharmacy organisations and integration within the NHS
At a national level, the main pharmacy organisations have begun to focus their efforts
on integrating pharmacy into national health improvement strategies. (Public Health:
A practical guide for community pharmacists 2004).
PharmacyHealthLink is an independent, registered charity that aims to promote and
improve the public’s health through pharmacy. In addition to research, the charity
65 Tann & Blenkinsopp, (2003).
66 Tann & Blenkinsopp, (2003), pp.1–2.
67 Blenkinsopp. Anderson & Armstrong, (2003). P.50.
69 The fpa (formerly The Family Planning Association) is a registered charity working to improve the
sexual health and reproductive rights of all people throughout the UK. It works with the public and
professionals to ensure high quality information and services are available to everyone who needs them.
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works on forming networks and coalitions to develop and influence policy, and on
providing appropriate training and information to encourage pharmacist involvement
in health improvement initiatives and public health. All this work is carried out in the
context of national health strategies and agendas.
In addition, the Pharmaceutical Services Negotiating Committee (PSNC) pressed for a
strong public health element to the new pharmacy contract and the National Pharmacy
Association’s (NPA) NHS Service Development Department (created in 1994)
responds to the challenges of the changing structure and administration in the NHS. It
aims to secure an expanded role for the community pharmacist in the provision of
healthcare, to work with local pharmacy leaders to secure adequate funding for that
role, and to facilitate the development of services locally. The Royal Pharmaceutical
Society of Great Britain includes among its remit responsibility for promoting good
practice and providing support for improvement. Its report, Pharmacy in a New Age,
which responded to changes at a national level also placed substantial emphasis on the
public health function of community pharmacy.
Policy changes have also played a part in encouraging community pharmacy
involvement in public health initiatives. Health Improvement Plans mention pharmacy
with increasing frequency and in Health Action Zones pharmacists have looked
carefully at local targets and funding sources and identified ways in which community
pharmacy can contribute.
At a local level, successive Government strategies have provided formal opportunities
for community pharmacy to become more closely integrated with other players in the
healthcare team. For example, in October 2002, Primary Care Trusts in England
assumed responsibility for developing community pharmacy services in their locality.
Local bodies such as local pharmaceutical committees can lend weight to potential
initiatives, particularly where these are compatible with local and national strategic
priorities and guidelines. They can also help bridge the gap between individual
pharmacists and local health commissioning bodies, ensuring that the needs of both
are met. In Glasgow, the Area Pharmaceutical Committee provided the organisational
and professional support to liaise with individual pharmacists about their involvement
in drug misuse issues and to link with the needs of the Health Board.
Other bodies such as the Pharmacy Development Groups (an initiative of the Royal
Pharmaceutical Society of Great Britain) also provide a valuable forum for sharing
information and ideas about current and future projects, and can help to co-ordinate
efforts to get new initiatives off the ground. The organisation of pharmacists into a
Pharmacy Steering Group within the Manchester, Salford and Trafford Health Action
Zone provided a forum for discussion and debate about how to take forward the
Health Action Zone priorities, and a unified voice to present ideas to Health Action
Zone officials. In both these cases, and that of the Glasgow Area Pharmaceutical
Committee, the groups played a key role in building partnerships with local authorities
– the Health Action Zone in Manchester and the Greater Glasgow Health Board/
Glasgow Drug Problem Service in Glasgow.
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Individual leadership
Case Study 1 demonstrated the importance of strong leadership and good project
management to champion the cause. All those interviewed constantly reiterated the
value of strong leadership. Particularly with innovative projects, there can be
formidable barriers to overcome at the outset – not just logistical but also political and
inter-professional. Pharmacy has traditionally been isolated from other health
professions. So skilled and motivated ‘champions’ within the profession can help to
overcome these difficulties. These key individuals can build links with other
healthcare providers with a potential highly positive knock-on effect for concurrent
and future projects. The ongoing developments augmenting and extending the
provision of drug use services in pharmacy for the Glasgow Case Study corroborated
this, as did the experience of providing EHC pilot services in Manchester, Salford and
Trafford and Lambeth, Southwark and Lewisham.
Fees and funding
The availability of funding (for example from Health Action Zones and central
smoking cessation and drug misuse funding) clearly influenced UK patterns of
activity. Pharmacists were paid for taking part in 60% of the projects surveyed and
these were most likely to be projects such as smoking cessation, sexual health and
drug misuse, where national funding was available.
In Case Studies 1 and 2, participating pharmacists emphasised their enthusiasm for
what they perceived was a necessary contemporary health service with an important
impact on public health. However, it was also clear that the fees pharmacists received
for the supply of services in each case were also an important motivation for their
participation – a finding collaborated by the Royal Pharmaceutical Society’s report.71
In determining the scope of health improvement, consideration must be given to the
commercial/business environment and the extent to which financial risk might
impinge on the willingness of pharmacy to be more heavily involved in initiatives of
this kind. Two-thirds of pharmacists are actually employees and the individual’s scope
for initiating or taking part in health improvement initiatives is relatively limited. As
one stakeholder in the case studies suggested, pharmacy multiple chains can have a
large influence on future policy.
Pharmacists’ reliance on funding meant that this was a critical factor for the success of
Case Studies 1 and 2. Funding was available primarily because both drug misuse and
EHC are high profile public health issues with important implications for social care
and – in the case of the Glasgow work – crime and public order. Funding bids were
supported by thorough evaluation research, audits and the development of clear
guidelines and service contracts with the commissioning agencies, all of which were
important elements in demonstrating successful outcomes. If the wider provision of
these services is to ensue, then funding needs to be available to support these
initiatives at a national, as well as at a local level.
71 Tann & Blenkinsopp, (2003). p.2.
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Outcome measures and evaluation
Only half of the projects identified specified outcome measures in their responses.
These measures ranged from full academic evaluations to the collection of minimal
data requirements – for example, four-week quit rates for smoking cessation or
numbers of clients accessing a particular service. Many of the projects identified by
the survey had not been properly evaluated. Less than a third reported some results,
and evaluation reports or summaries were received from just 3.2%.
The relevance of evaluation to secure funding has already been mentioned. Also, if
pharmacy-based projects are to receive recognition when they have an impact on local
health targets, they must be properly evaluated and robust evidence of outcomes
provided. A successful pilot initiative (which has been demonstrated to be successful,
preferably through independent evaluation) is highly influential in determining the
uptake and role-out of this type of service within the NHS. For example, many
primary healthcare organisations have now taken up the EHC models that were
developed in Manchester and in Lambeth Southwark and Lewisham.
Conclusion
Overall the survey showed a reasonable level of community pharmacist involvement
in local health improvement work, with the potential for developing and implementing
new services on a more widespread basis.
Compared with previous surveys, 72community pharmacy has clearly begun to engage
with the new NHS agenda and many areas have built working partnerships with key
local stakeholders. High awareness of developments in the health service was
identified as a common trait among innovators by the RPSGB report on innovation.73
Smoking cessation, sexual health and drug misuse were the most commonly reported
areas of activity. Service design, delivery and remuneration varied between Health
Authority areas. Examples from Europe, Australia and North America offer models
for diabetes, lipid management, weight management and immunisation schemes that
could be adapted and used as the basis for service development in the UK.
There are several key public health areas for which very few projects were identified
that have considerable potential for pharmacy participation. For example; obesity
programmes would contribute to the national target of reducing coronary heart disease
and stroke death rates in people under 75 years of age by at least 40% by 2010.74 And
reduction of overweight and obesity also appears in the cancer plan and is highly
relevant to inequality reduction. Similarly, every Primary Care Trust should have
72 Anderson, C Community pharmacy Health promotion activity in England: a survey of policy and
practice. Health Education Journal 1996; 55: 194-202
Anderson C Guidance for the development of health promotion by community pharmacists Pharm J
1998; 261: 771-775
73 Tann & Blenkinsopp, (2003), p.2.
74 Department of Health, (1999), p.2.
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schemes in place so that older people can get more help from pharmacists in using
their medicines.75
Significant progress has been achieved since the 1998 survey of activity76 but it is
unclear to what extent primary care organisations will use community pharmacy
services to help them meet their health improvement targets in the future and how
their performance will be assessed. However, the changes made to the structure of the
national pharmacy contracts to support the extended public health role of community
pharmacy will certainly facilitate this, thereby reducing the amount of local variation
and hence expectations of services available to pharmacy users
75 Department of Health, (2001), p.27.
76 Anderson C Guidance for the development of health promotion by community pharmacists Pharm J
1998; 261: 771-775
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Recommendations for the successful implementation of public health
initiatives in community pharmacy
This research enabled a number of common factors in local health improvement
initiatives to be identified that appear to be influential on the success of an initiative.
1. Stating and utilising the advantages of involving community pharmacy
The successful projects described above generally take advantage of a number of
factors unique to pharmacy. These include:
a) Community pharmacy’s role as a generic health provider. This helps to eliminate
potential stigma for sensitive health topics, such as supervised methadone
consumption.
b) Community pharmacy’s contact with both the sick and the healthy. This allows
pharmacists to contribute to preventative efforts such as screening, as well as
providing treatment for those who need it.
c) A large local network of pharmacies to facilitate access and opening times to suit
patients / customers for their convenience. This is important for projects requiring
the patient to make regular visits (e.g. supervised consumption of methadone) or
visits at short notice (e.g. emergency hormonal contraception).
d) Where possible, local bodies working on public health issues should initiate and
design projects specifically to take advantage of this potential that makes
pharmacy a valuable contributor for a wide range of health topics.
1. Planning
In particular Case Studies 1 and 2 illustrate the importance of the following
factors:
(a) Sourcing and securing dedicated funding.
(b) Building a committed network of participating pharmacies.
(c) Seeking the support of other health professionals.
(d) Supporting and promoting local pharmacy leadership (project champions)
(e) Facilitating multi-agency networking, partnerships, including service users.
 The chances of obtaining funding are significantly increased by tapping into
national agendas and selecting a target that is already an NHS priority, and by
making clear in any funding proposals exactly how the project will contribute to
meeting both local and national targets.
 Alternative sources of funding may be useful but may be a ‘one-off’ such as the
Royal Pharmaceutical Society’s Pharmacy in a New Age programme. This may,
for example, provide the possibility to employ a programme leader – a vital
contributor to project success – to ‘kick-start’ the project, but longer-term funding
will be needed for sustainability.
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 Remuneration systems clearly encourage participation and should be set-up where
appropriate funding permits. Fees should be arranged in such a way as to reward
longer-term commitment and better quality provision of services.
 Pharmacists can also be encouraged to participate through the selection of health
topics that are specifically relevant to their local areas and their clients.
 The support of the right organisations and other healthcare professionals is crucial
to success and they will need to be consulted and involved early on in the project.
 Using local bodies, such as the Local Pharmaceutical Committees or Pharmacy
Development Groups, can provide valuable support for seeking funding and
establishing contracts for service provision.
 Approaching local health service commissioners using the language and referring
to the targets that they are interested in.
 Knowing the details of the local Health Improvement Programme and identifying
relevant topic areas.
1. Implementation
a) Use written patient contracts where appropriate, for example in drug misuse
services.
b) Provide a private consultation area in the pharmacy.
c) Carry out careful and thorough evaluation of the service, including users’
views.
d) Arrange multidisciplinary training where possible.
 All pharmacy public health initiatives involve interaction with the public and some
element of advice and information provision. As the advice-giving role of
community pharmacists on general health issues is not widely recognised or
utilised,77 schemes that encourage the public to approach pharmacists may require
additional training to encourage pharmacists to be more proactive. Communication
skills should constitute a substantial part of any training provision as this will
better prepare the reticent pharmacist for contact with the public, will reassure
unconfident service users and will translate into better service provision.
 Patient contracts are an effective way of emphasising the commitment inherent in
participating in a given scheme.
 Efforts should be made to provide the appropriate environment to facilitate the
type of consultation that patients/customers want with their pharmacist. The Case
Studies in Report 2 of the evidence base indicate that privacy and confidentiality
remain concerns for a significant number of users of pharmacy services and may
77 Blenkinsopp, Anderson & Armstrong, (2003). p.40.
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discourage some people from coming forward.78 Publicise the pharmacist’s duty to
ensure confidentiality.
 Efforts should also be made to reduce the stigma associated with certain
treatments such as emergency hormonal contraception and methadone by being
sensitive to the issues involved. And in particular by providing appropriate
privacy, confidentiality and a non-judgemental manner.
 Build careful record keeping into the original project design.
 Outcome measures should be made clear from the start and should reflect
government targets wherever possible to allow for later collation of evidence.
 Funds must be allocated in advance to allow for thorough evaluation, and results
should be publicised, at least locally. Independent evaluation is always preferable
where funding allows.
 Guidelines for service provision should be established in advance and audit should
be carried out.
 Training should be consistent to provide a high quality evidence based service.
Nationally recognised standards should be used wherever possible but training
should also be adapted to specific local projects and to pharmacists’ needs.
 Strong signage in pharmacies and other displays of materials encouraging clients
to approach the pharmacist should also be used.
78 Blenkinsopp, Anderson & Armstrong, (2003). p.35–36.
Final Report 2005
46
References
Ahmed, S. (2001). Drug Injectors. In AIDS (Control) Act Report 2000-2001, pp.8–9.
Official Journal of the International Aids Society 15: 2171-2179 9Nov 2001.
Anderson, C. (1996). Community pharmacy Health promotion activity in England: a
survey of policy and practice. Health Education Journal 55: 194–202.
Anderson, C. (1998). Guidance for the development of health promotion by
community pharmacists. Report for the Pharmacy Healthcare Scheme and the
Department of Health. King’s College London.
Anderson, C., Bissell, P., Sharma, S. & Sharma, R. (2001a). The Manchester, Salford
and Trafford Health Action Zone Emergency Contraception Service: Evaluation
Report. University of Nottingham
Anderson, C. Blenkinsopp, A. & Armstrong, M. (2003). The contribution of
community pharmacy to improving the public’s health. Report 1. Evidence from the
peer-reviewed literature 1990–2001. London: PharmacyHealthLink and the Royal
Pharmaceutical Society of Great Britain.
Blenkinsopp, A., Anderson, c. & Armstrong, M (2003). The contribution of
community pharmacy to improving the public’s health. Report 2. Evidence from the
UK non-peer reviewed literature 1990–2002. London: PharmacyHealthLink and the
Royal Pharmaceutical Society of Great Britain.
Audit Commission, (2002). Changing habits: the commissioning and management of
drug treatment services for adults. Oxford: Audit Commission.
Department of Health, (1998). Our Healthier Nation – A contract for Health. London:
HMSO.
Department of Health, (1999). Saving Lives: Our Healthier Nation. London: HMSO.
Department of Health, (2001). National service framework for older people –
Medicines and older people. London: Department of Health.
Ellertson, C., Shochet, T., Blanchard, K. & Trussell, J. (2000). Emergency
contraception: a review of the programmatic and social science literature.
Contraception. 61: 145–86.
Frischer, M., Goldberg, D., Taylor, A. & Bloor, M. (1997). Estimating the incidence
and prevalence of injecting drug use in Glasgow. Addiction Research. 5(4): 307–315.
Glasier, A. (1997). Emergency postcoital contraception. New England Journal of
Medicine 337: 1058–1064. 1997 9Oct.
Hadley, A. (1995). Picking up the pieces. Practice Nurse. Vol.10 No3 169
ISSN 0 953-6612
Final Report 2005
47
ISD(2002). Drug Misuse Statistics Scotland 2002 Edinburgh
www.drugmisuse.isdscotland.org
Lambeth, Southwark and Lewisham Health Action Zone (2001) A timely service: a
Lambeth, Southwark and Lewisham Health Action Zone project on access to
emergency hormonal contraception via accredited community pharmacies. [Available
on-line: www.lslhaz.org.uk/options.htm (accessed 18/04/02)]
McLoed, A. (2001). Changing patterns of teenage pregnancy: population based study
of small areas. British Medical Journal 323: 199–203.
O’Brien, K. & Gray, N. (2000). Supplying emergency hormonal contraception in
Manchester under a group prescribing protocol. Pharmaceutical Journal 264: 518–
519.
Roberts, K. (2000). Guidelines for supervision of methadone consumption in
pharmacies. Glasgow: Greater Glasgow Health Board, Primary Care Trust and Area
Pharmaceutical Committee.
Roberts, K., McNulty, H., Gruer, L., Scott, R. & Bryson, S. (The role of Glasgow
pharmacists in the management of drug misuse. International Journal of Drug Policy
Volume 9: 187–194. ISSN 0955-3959
Rousanville, B.J. & Kosten, T.R. (2000). Treatment of opiod dependence: quality and
access. JAMA 283(10): 1337–1339.
Savage, I. (2001). Community pharmacy supply of emergency contraception: a service
begging to be done. Final Evaluation report of a pilot scheme to permit community
pharmacists to supply emergency contraception under a Patient Group Direction.
London
Scottish Office Home and Health Department (1994). The role of pharmaceutical
services in Drugs in Scotland: meeting the challenge. Report 4, pp.41–54.
Edinburgh: Ministerial Drugs Task Force.
Seston, E.M. (2002). The impact of the de-regulation of emergency hormonal
contraception on a PGD scheme in NW England. International Journal of
Pharmaceutical Practice Smith, I. Cantrill, J.A. O’Brien, K.
Social Exclusion Unit. (1999). Teenage pregnancy. London: Stationery Office.
Tann, J & Blenkinsopp, A. (2003). Understanding innovation in community pharmacy
– an interim report. London: Royal Pharmaceutical Society of Great Britain.
Taylor, A., Goldberg, D., Hutchinson, S., Cameron, S., Gore, S.M., McMenamin, J.,
Green, S., Pithie, A. & Fox, R. (2000). Prevalence of hepatitis among injecting drug
misusers in Glasgow 1990–1996: are current harm reduction strategies working?
Journal of Infection 40: 176–183.
Final Report 2005
48
Weinrich, M. & Stuart, M. (2000). Provision of methadone treatment in primary care
review of the Scottish experience and implications for US policy. JAMA 283(10):
1343–1348.
